Wouter de Herder - Selected Publications#

h-index (SCOPUS): 87
h-index (Google Scholar): 94
h-index (Web of Science): 76

Zandee WT, Kamp K, van Adrichem RC, Feelders RA, de Herder WW (2016). Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. Eur J Endocrinol. 175(5): 361-366.

Zandee WT, van Adrichem RC, Kamp K, Feelders RA, van Velthuysen MF, de Herder WW (2017). Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf). 87(2): 165-170.

Zandee WT, Kamp K, van Adrichem RCS, Feelders RA, de Herder WW (2017). Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. Endocr Relat Cancer. 2017 24(7): R261-R274.

Blazevic A, Hofland J, Hofland L, Feelders RA, de Herder WW (2018). Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. Endocr Relat Cancer. 25(3): 115-R130.

Blazevic A, Zandee WT, Franssen GJH, Hofland J, Van Velthuysen MF, Hofland L, Feelders RA, de Herder WW (2018). Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocr Relat Cancer. 25(3): 245-254.

Zandee WT, Brabander T, Blaževic A, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, de Herder WW (2019). Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 104(4): 1336-1344.

Zandee WT, Feelders RA, Smit Duijzentkunst D, Hofland J, Metselaar RM, Oldenburg RA, van Linge A, Kam BLR, Teunissen J, Korpershoek E, Hendriks J, Abusaris H, Slagter C, Franssen GJH, Brabander T, de Herder W (2019). Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Eur J Endocrinol. 181(1): 45-53.

Hofland J, Kaltsas G, de Herder WW (2020). Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 41(2): 1-33.

Zandee WT, Brabander T, Blažević A, Minczeles NS, Feelders RA, de Herder WW, Hofland J (2021). Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome. J Clin Endocrinol Metab. 106(9): e3665-e3672.

Blazevic A, Starmans MPA, Brabander T, Dwarkasing RS, van Gils RAH, Hofland J, Franssen GJH, Feelders RA, Niessen WJ, Klein S, de Herder WW (2021). Predicting symptomatic mesenteric mass in small intestinal neuroendocrine tumors using radiomics. Endocr Relat Cancer. 28(8): 529-539.